Incyte Partners with Halozyme to Develop Subcutaneous INCA033989

Shots: Incyte has entered into a global collaboration & license agreement with Halozyme to evaluate additional SC formulations of INCA033989 for pts with mutCALR-expressing myeloproliferative neoplasms, using Halozyme's Enhanze tech As per the deal, Halozyme will receive an upfront payment, as well as milestone payments, plus royalties, with Incyte having an option to nominate up…

ByRidhi Rastogi1 day ago

Incyte Reports Positive P-I Data of INCA033989 in Essential Thrombocythemia (ET) at ASH 2025

Shots: Incyte reported updated data from two P-I trials showing the safety, tolerability, and efficacy of INCA033989 (INCA33989-101 and INCA33989-102) in 455 adults(age≥18) with mutCALR-positive MPNs, including ET & MF, findings were presented at ASH'25 In ET pts receiving higher starting doses of INCA033989 (400–2,500 mg; n=30), 90% achieved a HR, including 83.3% with CHR…

ByDipanshu DixitDecember 9, 2025

Incyte Partners with Enable Injections for enFuse On-Body Delivery System

Shots: Incyte has partnered with Enable Injections to develop and commercialize specific assets in Incyte’s portfolio, incl. INCA033989, a mutCALR selective mAb, with Enable’s enFuse On-Body Delivery System As per the deal, Incyte will obtain exclusive global rights to use enFuse tech with INCA033989 for essential thrombocythemia & myelofibrosis, with potential expansion to other assets &…

ByRidhi RastogiOctober 28, 2025

Incyte Partners with Halozyme to Develop Subcutaneous INCA033989

Incyte Reports Positive P-I Data of INCA033989 in Essential Thrombocythemia (ET) at ASH 2025

Incyte Partners with Enable Injections for enFuse On-Body Delivery System

Contact US

FOLLOW US